Six Chinese Gene Therapy Companies Secure New Funding Rounds
Anlong
Gene Therapy Drug Developer
StarryGene
Gene Therapy Drug Developer
▎WuXi AppTec Content Team Report
According to the Jike Pharma Database, as of June 21, there were 420 financing cases in the global innovative drug sector in the first half of 2024. In terms of financing rounds, there were 203 cases of early-stage financing (before Series B), accounting for about 48%.In terms of research areas, small molecule drugs, cell and gene therapies, and antibody-based drugs are the three fields with the most financing events.
In China, a total of 88 financing events occurred in the first half of 2024 (As of June 21），Among themEarly-stage financing(B round before)There are 54 cases, accounting for over 60%.。From the perspective of research fields,The cell and gene therapy field remains one of the key focuses of the industry. Recently, we have shared the financing obtained in the first half of the year.Cell Therapy CompanySituation. Today, we will share several companies that have received financing.Chinese Gene TherapyBasic Information of New锐 Company, for Readers' Reference Only。Scan the end of the articleQR code to access the list of "Chinese Innovative Drug Companies with Financing Amounts Exceeding 100 Million Yuan in the First Half of 2024."
Image Source: 123RF
Anlong
Established: 2019
Financing Round:Series A+
News on January 23: Anlong announced the completion of a multi-million-dollar A+ round of financing. This round of financing was jointly invested by Tai Kun Fund and Shun Chuang Industry Investment Management Fund. Anlong was established in 2019 and is committed to utilizing breakthrough advancements in molecular biology for the research and development of gene drugs.Including the application of gene regulation, gene therapy, gene editing and other technologiesThe chairman and CEO of the company is Dr. Chunlin Zhao.Anlong Biotech's self-developedAAV Gene Therapy Drug AL-001 Ophthalmic InjectionBeing carried out in China forAge-related Macular Degeneration (Wet Form)Clinical trials. This timeThe financing funds will be used to advance the clinical trials of the AAV gene therapy product AL-001 and the research and development of innovative small nucleic acid drugs.
Financing Round:Angel Round
StarryGene
Established: 2019
Financing Round:Pre-A+Wheel
News on March 19, StarryGene announced the completion of a Pre-A+ round of financing worth tens of millions of RMB, led byCayman Venture CapitalLed by, with follow-up investments from Hefei Innovation Investment (Hefei High-Level Talent Project) and other institutions.StarryGene was founded in 2019,Focusing on the development of ophthalmic gene therapy drugs, the companyFounder, CEO isDr. Cai Yuan。Currently,StarryGene's self-developed gene therapy Class 1 innovative drug XMVA09 injection has previously been approved for clinical trials in China.Thisis a product that combinesAchieving Bispecific TargetingAndIntravitreal Injection CapsidGene therapy drugs,Intended for development in wAMD。
Financing Round:Pre-A+Round
Financing Round:SeedRound
Longgene
Financing Round:Series B+
June 11,Longxin BioAnnounced the completion of the B+ round of financing, which was led by the Shanghai Biomedical Fund, with co-investment from shareholders such as United Investment.Lanxin Bio was founded in 2020.Dedicated to the research and development of innovative gene therapy drugs for the treatment of hereditary and chronic eye diseases.The founder and CEO of the company is Dr. Wang Fenghua.
Currently, Anlong has 5 candidate molecules entering clinical trials and has obtained 3 IND approvals. The companyDeveloped byLX101 is currently under treatment.RPE65Mutation-Associated Inherited Retinal Dystrophy (IRD)Phase 3 clinical trial; LX102 is currently being developed for the treatmentWet Age-related Macular DegenerationPhase 2 clinical trial; LX103 is currently being developed for the treatmentX-linked RetinoschisisTheInvestigator-Initiated ClinicalTest（IIT）。
In addition to the aforementioned companies, many other Chinese innovative drug companies also announced financing progress in the first half of this year.，Due to space limitations, this article will not go into details one by one. It is hoped that with the support of capital, these biopharmaceutical companies can accelerate the R&D progress of candidate drugs and bring new treatment options to the majority of patients as soon as possible.
Scan the QR code below to accessChinese Innovative Drug Companies with Financing Amounts Exceeding 100 Million Yuan in the First Half of 2024List (Free Download for a Limited Time).
References:
[1] Public information and official press releases from various companies.
This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media platforms, but unauthorized republication by media or organizations in any form to other platforms is strictly prohibited. For authorization to republish, please contact us via a message on the "MedView" WeChat Official Account. For other cooperation inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it mean that WuXi AppTec supports or opposes the views in the article. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a regular hospital.
